Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
“This was an exciting confirmation of our findings and their applicability to human disease,” Dr. Shah says. “Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia. This suggests that sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.”
The Mayo study showed that deposits of fibrin — microvascular blood clots — contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
“Neutrophils had not previously been identified as significant drivers of portal hypertension,” says Moira Hilscher, M.D., the paper’s first author. Results were verified in two different models of chronic liver disease.
“The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces,” says Dr. Hilscher. “Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need.”
The Latest on: Liver diseases
via Google News
The Latest on: Liver diseases
- Liver disease up in young adults, with possible tie to pandemic-related drinking, UW Health sayson April 10, 2021 at 3:15 am
A rise in liver disease among young people, especially women, may be tied to increased drinking related to stress from the pandemic, a UW Health doctor said. Dr. Rita German, a transplant liver ...
- INTERVIEW: Liver disease increasing among younger adultson April 9, 2021 at 3:44 pm
Doctors are seeing an increase in liver disease among adults age 25 to 34, particularly in young women. Dr. Rita German, a transplant hepatologist, at U.W. Health, is studying this trend. Her research ...
- Significant Nonalcoholic Fatty Liver Disease, Fibrosis Risk Found in Patients With Obstructive Sleep Apneaon April 9, 2021 at 8:03 am
Approximately 45% of patients with obstructive sleep apnea were shown to present with nonalcoholic fatty liver disease, with age and weight indicated as significant predictors of high fibrosis score ...
- Liver Disease Is On The Rise In Young Women, Mothers Includedon April 8, 2021 at 2:03 pm
Treatment specialists are reporting an uptick in women seeking treatment, and doctors are reporting much higher rates of alcoholic liver disease in women. Jessica Mellinger, MD, a liver specialist ...
- Deaths from liver diseases skyrocket in South Dakota amid COVID-19 pandemicon April 8, 2021 at 1:56 pm
For the last decade, yearly deaths from cirrhosis and liver disease have been ticking up. But 2020 saw the steepest jump yet.
- Liver Diseases and Transplantation Centreon April 8, 2021 at 6:24 am
Kauvery Group of Hospitals launched Centers of Excellence CoE - The Kauvery Liver Diseases and Transplantation Centers - across all units - Chennai Trichy S ...
- Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progressionon April 8, 2021 at 3:00 am
The inhibitory effects of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) modulates T-cell depletion. T-cell depletion is one of the key mechanisms of hepatitis B virus (HBV) ...
- Bariatric Surgery May Cut Cancer in Obesity With Liver Diseaseon April 7, 2021 at 5:30 am
Among working adults with severe obesity and fatty liver disease, rates of cancer were lower for those who had bariatric surgery, especially those with obesity-related cancer, during a 10-month median ...
- Maddening itch of liver disease comes from a surprising sourceon April 6, 2021 at 4:16 pm
A devastating itching of the skin driven by severe liver disease turns out to have a surprising cause. Its discovery points toward possible new therapies for itching, and shows that the outer layer of ...
- Alcohol-related liver disease on the rise among young women amid increased pandemic drinkingon April 6, 2021 at 1:04 am
She said she had "no idea" that someone her age could end up so quickly with alcohol-related liver disease, nor did she know that she may be more susceptible to medical complications from her drinking ...
via Bing News